Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Users of Dermal Fillers (US)

Articles with lock require a subscription to GLG News | Request a free trial
May 29, 2007
Already here....
Analysis of: Getting a Discount on Plastic Surgery | online.wsj.com
Author: Michael Bain, Plastic and Reconstructive Physician, Michael A Bain, MD
Discount cosmetic surgery is already here, but not via large commercial companies.  Retention of actual plastic and reconstructive surgeons may be difficult if they are not paying well.  There is a place for this, however the solo practitioner will continue to have word of mouth and a place....
May 29, 2007
New Organiceuticals May Help Bring Back Beauty!
Analysis of: http://www.nytimes.com/2007/04/26/fashion/26skin.html?_r=1&ref=health&oref=slogin | www.nytimes.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
All that glitters is not gold...but some might be! Anti-oxidants are the promise of saving our "hides"!
May 29, 2007
FDA ban on Hydroquinones
Analysis of: FDA May Place Ban on OTC Bleaching Creams | www.carefair.com
Author: GLG Expert Contributor
I have yet to see any study that would prclude me from recommending these products. I believe if utilized correctly and dosed appropriately it would be a disservice to our patients if the ability to prescribe this were taken away.
May 28, 2007
Couldn't agree more
Analysis of: FDA May Place Ban on OTC Bleaching Creams | www.carefair.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
Keep Hydroquinones Around!
Sunil DhawanMay 24, 2007
FDA Hydroquinone ban may be premature
Analysis of: FDA May Place Ban on OTC Bleaching Creams | www.carefair.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The possible ban of over the counter hydroquinone skin bleaching agents may be premature. We have used these agents for 20 years without any significant side effects including ochronosis or paradoxical darkening of the skin. These agents are only modestly effective at best. Most patients still...
May 17, 2007
Non-Invasive Screening of the Skin
Analysis of: New tool allows noninvasive screening of skin lesions | www.modernmedicine.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
The company hopes to apply for European regulatory approval next year, with U.S. market approval and launch to follow. The current price of the device is 15,000 EUR. This device promises to be a remarkable time and money saver for medicine. Approximately 80-95% of lesions excised by dermatologists prove...
May 17, 2007
Pulsed Dye Vs Excimer Laser for Psoriasis
Analysis of: Psoriasis Challenge: pulsed dye vs. excimer lasers | www.modernmedicine.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
Patient satisfaction is high, but long term effects including possible carcinogenesis remain uncertain. Side effects included blistering, and hyperpigmentation in both groups, but no scarring.
May 15, 2007
For wounds, it is going to happen
Analysis of: Home telemonitoring works, study claims | www.healthcareitnews.com
Author: Michael Bain, Plastic and Reconstructive Physician, Michael A Bain, MD
In the Plastic Surgery literature wound care via home monitoring is advanced enough to change outcomes.  See Murphy, Bain et al in the Annals of Plastic Surgery June 2005. Home telemonitoring is good for certain problems, that require regular monitoring.  It has been shown to be equivalent...
Sunil DhawanMay 4, 2007
Ceragenix Epiceram product phase 4 results positive
Analysis of: Ceragenix Announces Results from Phase IV Study of EpiCeram(TM) Meet All Primary and Secondary Endpoints | www.irconnect.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The recent Epiceram phase 4 data comparing it to Cutivate are positive, and bode well for the product. The concept of barrier repair makes sense in light of the recent findings in regards to the genetic basis of atopic dermatitis. Repairing the barrier with Epiceram will reduce inflammation, and the...
Sunil DhawanApril 23, 2007
Altabax will have good sales in the impetigo market
Analysis of: FDA Approves Antibiotic Ointment For Children And Adults - Altabax (retapamulin Ointment) | www.medicalnewstoday.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Altabax (retapamulin) will be a competitive topical agent for impetigo because it is a new molecular entity, Bactroban or mupirocin is generic and cannot compete directly, and it is indicated for children as young as 9 months. The market for a nonoral antibiotic is always good, due to lower side ef...

Previous Page : 1 2 3 4 5 6 7 8 9 10 Next71 to 80 of 100

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-04T13:45:22.160